Alison Moore
Director/Board Member at CODEXIS, INC.
Net worth: 2 M $ as of 2024-04-29
Profile
Presently, Alison Moore occupies the position of Chief Technical Officer at Allogene Therapeutics, Inc. Dr. Moore is also on the board of Codexis, Inc. In the past Dr. Moore occupied the position of Senior Vice President-Process Development at Amgen, Inc. and Director-Chemistry, Manufacturing & Controls at Genentech, Inc. Alison Moore received a doctorate and an undergraduate degree from The University of Manchester.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
2023-03-21 | 670,173 ( 0.39% ) | 2 M $ | 2024-04-29 | |
CODEXIS, INC.
0.10% | 2024-04-17 | 68,576 ( 0.10% ) | 181 726 $ | 2024-04-29 |
Alison Moore active positions
Companies | Position | Start |
---|---|---|
CODEXIS, INC. | Director/Board Member | 2020-06-15 |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Director/Board Member | - |
Former positions of Alison Moore
Companies | Position | End |
---|---|---|
ALLOGENE THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2023-04-27 |
AMGEN INC. | Corporate Officer/Principal | 2018-05-31 |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | General Counsel | 2005-12-31 |
Training of Alison Moore
The University of Manchester | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 3 |
---|---|
AMGEN INC. | Health Technology |
ALLOGENE THERAPEUTICS, INC. | Health Technology |
CODEXIS, INC. | Process Industries |
Private companies | 2 |
---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
- Stock Market
- Insiders
- Alison Moore